KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, Krish Patel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Marie Hughes, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, George Follows, Patricia Walker, Paolo Ghia, Ann Janssens, John C Byrd, Emmanuelle Ferrant, Alessandra Ferrajoli, William G Wierda, Catherine Wangui Wachira, Batul T Suterwala, Paulo Miranda, Veerendra Munugalavadla, Chuan-Chuan Wun, Jennifer A Woyach

Blood 146(11) 1276-1285

PMID40198878
PMCIDPMC12824692
DOI10.1182/blood.2024024476
发表日期2025-04-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia. We present results from ELEVATE-TN after a median follow-up of 74.5 months. Overall, 535 patients were randomized (acalabrutinib-obinutuzumab, n = 179; acalabrutinib, n = 179; chlorambucil-obinutuzumab, n = 177). Median age was 70 years, 63.0% had unmutated immunoglobulin heavy chain variable region gene (uIGHV), 13.6% had del(17p) and/or mutated TP53, and 17% had complex karyotype (CK; ≥3 chromosomal abnormalities). Median progression-free survival (PFS) was not reached (NR) for acalabrutinib-obinutuzumab and acalabrutinib vs 27.8 months for chlorambucil-obinutuzumab (both P < .0001); estimated 72-month overall PFS rates were 78.0%, 61.5%, and 17.2%, respectively. Acalabrutinib-obinutuzumab resulted in improved PFS vs acalabrutinib monotherapy (hazard ratio [HR], 0.58; P = .0229). Patients with uIGHV, del(17p) and/or mutated TP53, or CK had significantly improved PFS with acalabrutinib ± obinutuzumab vs chlorambucil-obinutuzumab (P < .0001, P ≤ .0009, and P < .0001 for both acalabrutinib-containing arms, respectively). Median overall survival (OS) was NR for all treatments, with significantly longer OS for acalabrutinib-obinutuzumab than chlorambucil-obinutuzumab (HR, 0.62; P = .0349). Estimated 72-month OS rates were 83.9%, 75.5%, and 74.7% for acalabrutinib-obinutuzumab, acalabrutinib, and chlorambucil-obinutuzumab, respectively. Adverse events (AEs) occurring after >4 years were mostly grade 1 to 2. Rates of AEs, serious AEs, and events of clinical interest were similar between acalabrutinib-containing arms and consistent with the known safety profiles of acalabrutinib and obinutuzumab. Efficacy and safety of acalabrutinib-containing arms were maintained, with longer PFS in both acalabrutinib arms than chlorambucil-obinutuzumab including in patients with high-risk features. This trial was registered at www.ClinicalTrials.gov as #NCT02475681.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1

Figure 1. Investigator-assessed PFS overall. ∗HR based on stratified Cox proportional hazards model; † P value based on stratified log-rank test. ‡HR based on unstratified Cox proportional hazards model; § P value based on unstratified log-rank test. A, acalabrutinib; Clb, chlorambucil; O, obinutuzumab.

Figure_1

progression-free survival

Figure 1 · Panel Figure_1

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel Figure_1 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Figure 3

Figure 3. OS in patients overall. ∗HR based on stratified Cox proportional hazards model; † P value based on stratified log-rank test. ‡HR based on unstratified Cox proportional hazards model; § P value based on unstratified log-rank test. Clb, chlorambucil.

OS_in_patients_overall

Overall survival

Figure 3 · Panel OS_in_patients_overall

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel OS_in_patients_overall 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 2Figure 2. ORRs∗ and CR/CRi rates over follow-up period in patients treated with A-O or A monotherapy. ∗Best investigator-assessed response could be determined at any scheduled, per-protocol follow-up visit. ORR is defined as achieving CR, CRi, nPR, or PR per the investigator per International Workshop on CLL 2008 criteria at or before initiation of subsequent anticancer therapy. ORR does not include partial response except for lymphocytes. A, acalabrutinib; nPR, nodular partial response; O, obinutuzumab; PR, partial response.
非 KM Figure